274 related articles for article (PubMed ID: 28062546)
1. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
Foulkes SJ; Daly RM; Fraser SF
Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
[TBL] [Abstract][Full Text] [Related]
4. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
[TBL] [Abstract][Full Text] [Related]
5. Abdominal visceral fat measurement using dual-energy X-ray: association with cardiometabolic risk factors.
Rothney MP; Catapano AL; Xia J; Wacker WK; Tidone C; Grigore L; Xia Y; Ergun DL
Obesity (Silver Spring); 2013 Sep; 21(9):1798-802. PubMed ID: 23696250
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
7. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
[TBL] [Abstract][Full Text] [Related]
8. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.
Nilsen TS; Raastad T; Skovlund E; Courneya KS; Langberg CW; Lilleby W; Fosså SD; Thorsen L
Acta Oncol; 2015 Nov; 54(10):1805-13. PubMed ID: 25927504
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
[TBL] [Abstract][Full Text] [Related]
10. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
11. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
12. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy.
Hamilton EJ; Gianatti E; Strauss BJ; Wentworth J; Lim-Joon D; Bolton D; Zajac JD; Grossmann M
Clin Endocrinol (Oxf); 2011 Mar; 74(3):377-83. PubMed ID: 21118287
[TBL] [Abstract][Full Text] [Related]
13. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
16. The influence of androgen deprivation therapy on hip geometric properties and bone mineral density in Japanese men with prostate cancer and its relationship with the visceral fat accumulation.
Watanabe D; Kimura T; Yamashita A; Minowa T; Miura K; Mizushima A
Aging Male; 2020 Dec; 23(5):1158-1164. PubMed ID: 31959023
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the Bertin index to estimate visceral adipose tissue from dual-energy X-ray absorptiometry and cardiometabolic risk factors before and after weight loss.
Karelis AD; Rabasa-Lhoret R; Pompilus R; Messier V; Strychar I; Brochu M; Aubertin-Leheudre M
Obesity (Silver Spring); 2012 Apr; 20(4):886-90. PubMed ID: 21869764
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
19. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
20. Current and future strategies for the nutritional management of cardiometabolic complications of androgen deprivation therapy for prostate cancer.
Turner L; Poole K; Faithfull S; Griffin BA
Nutr Res Rev; 2017 Dec; 30(2):220-232. PubMed ID: 28606220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]